- Company
- Risk of Impurities in Treatment of Schizophrenia
- by Chon, Seung-Hyun May 4, 2022 06:04am
- The health authorities have started to check for impurities on Quetiapine-based drugs used as schizophrenia treatments. It is a new type of nitrosamines impurity that has not appeared before. The number of drugs that have raised the risk of impurities in Korea has increased to 10. According to the industry on the 3rd, the MFDS recently ord
- Company
- Insurance benefit for Vemlidy expanded in Korea
- by May 4, 2022 06:03am
- The health authorities have extended the insurance benefit of Gilead Science’s chronic hepatitis B treatment ‘Vemlidy (tenofovir ala fenamide)’ to liver cirrhosis and hepatocellular carcinoma, accelerating the generation shift of HBV drugs in Korea. According to the Ministry of Health and Welfare on the 3rd, Vemlidy’s reimbursement sta
- Company
- Boryung challenges patent for leukemia drug Tasigna
- by Kim, Jin-Gu May 4, 2022 06:03am
- Boryung has challenged Novartis' patent for its leukemia treatment Tasigna (Nilotinib). If the patent avoidance challenge is successful, Boryung is expected to be able to aim for synergy with the previously released Glivec (Imatinib mesilate) generic. According to the pharmaceutical industry on the 3rd, Boryung recently requested a passive
- Company
- The first oral GLP-1 Novonodisc's Rybelsus was approved
- by May 4, 2022 06:03am
- The world's first oral GLP-1 analog has landed in Korea. Novonodisk announced on the 3rd that it has obtained an item license from the MFDS for oral GLP-1 analog-based type 2 diabetes treatment Rybelsus (Semaglutide). Rybelsus is used as a dietary and exercise therapy supplement to improve blood sugar control in adults who do not have suff
- Company
- When will the discussion on Dupixent's benefit be concluded?
- by Eo, Yun-Ho May 3, 2022 06:09am
- It does not seem easy for Dupixent, an atopic dermatitis treatment, to expand insurance benefits for children and adolescents. According to related industries, Standard of Sanofi-Aventis Korea's Dupixent 200mg was recently set. It is the first time in about a year since the application for expansion of benefits in March 2021. Dupixent's expan
- Company
- Cephalosporin CMOs discontinue or downsize business
- by Kim, Jin-Gu May 3, 2022 06:09am
- CMO companies that have been manufacturing cephalosporin antibiotics upon consignment are either shutting down or reducing their business one after another. Given the limited number of domestic manufacturers, existing consignors are in a rush to find new consignees. Due to this, industry concerns are rising over how this breakaway among c
- Company
- GSK Consumer Healthcare Korea appoints Dongwoo Shin as CEO
- by May 3, 2022 06:09am
- GSK Consumer Healthcare Korea announced that it has appointed Dongwoo Shin (55) as the new head of its Korean subsidiary. The new General Manager has graduated from Hanyang University with a BA in Philosophy and a MA in Philosophy from the University of Rochester. After serving in various companies including Coca-Cola Korea, 20th Century
- Company
- COVID-19 vaccine SKYCovione has been applied
- by Kim, Jin-Gu May 3, 2022 06:08am
- SK Bioscience announced on the 29th that it has applied for an item permit for the COVID-19 vaccine candidate GBP510. SK Bioscience predicted that it will be able to commercialize it in the second half of the year after obtaining approval from the MFDS. The name of the vaccine applied through item approval was SKYCovione Multi Injection
- Company
- Generics for Xarelto with sales of ₩60 billion are com
- by Kim, Jin-Gu May 3, 2022 06:08am
- Competition of generic products is in full swing in the new oral anticoagulant (NOAC) market of Rivaroxaban ingredients worth 60 billion won a year. With more than 20 companies' generics pouring in in earnest since the fourth quarter of last year, Chong Kun Dang seems to be one step ahead. In the pharmaceutical industry, it is analyzed that t
- Company
- Nerlynx reattempts at reimb after failing CDDC review
- by Eo, Yun-Ho May 2, 2022 06:03am
- An adjuvant therapy drug for breast cancer, Nerlynx, that failed to receive reimbursement in its first attempt is reattempting reimbursement in Korea. According to industry sources, Bixink Therapeutics plans to apply for insurance benefits for its oral HER2 inhibitor Nerlynx (neratinib) in the second half of this year. The drug reached
